Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 22/2003

01-11-2003 | Review Article

Drug Therapy for Adults with Attention-Deficit Hyperactivity Disorder

Author: Dr Timothy E. Wilens

Published in: Drugs | Issue 22/2003

Login to get access

Abstract

Practitioners are increasingly called upon to diagnose and treat attention deficit hyperactivity disorder (ADHD) in adults. Although the use of pharmacotherapy in children with ADHD is well studied, the use of drugs for the treatment of adults with ADHD remains less well established.
A systematic review of the literature identified 15 studies (n = 482 patients) of stimulants, and 27 studies of nonstimulant medications (n = 1179 subjects) including antidepressants, norepinephrine reuptake inhibitors, antihypertensive agents, amino acids and wake-promoting agents for the treatment of ADHD in adults.
Controlled clinical trials in adults showed that stimulants, antidepressants and norepinephrine reuptake inhibitors demonstrated significant short-term improvements in ADHD symptoms compared with placebo. The two longer term trials with methylphenidate in adults confirmed the ongoing effectiveness and tolerability of stimulants. The response to amphetamine and methylphenidate appears to be dose-dependent. Methylphenidate and amphetamine had an immediate onset of action, whereas responses to pemoline, antidepressants and norepinephrine reuptake inhibitors appeared delayed. Controlled data on nicotinic/cholinergic compounds appear promising. Considerable variability was found in the diagnostic criteria for ADHD in adults, drug dosages and response rates between the various studies.
Under controlled conditions, the aggregate literature comprised mainly of short-term studies, shows that stimulants, norepinephrine reuptake inhibitors and specific antidepressants had clinically and statistically significant beneficial effects in the treatment of ADHD in adults. Cholinergic agents appear promising. Further studies are necessary to evaluate the long-term effectiveness and tolerability of various agents, functional and neuropsychological outcomes, and the use of various agents in specific subgroups of adults with ADHD.
Footnotes
1
Use of tradenames is for product identification purposes only and does not imply endorsement.
 
Literature
1.
Bauermeister JJ, Canino G, Bird H. Epidemiology of disruptive behavior disorders. In: Greenhill L, editor. Child and Adolescent Psychiatry Clinics of North America. Philadelphia (PA): WB Saunders Company, 1994: 177–94
2.
Murphy K, Barkley RA. Prevalence of DSM-IV symptoms of ADHD in adult licensed drivers: implications for clinical diagnosis. J Atten Disord 1996; 1(3): 147–61CrossRef
3.
Goldman L, Genel M, Bezman R, et al. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. JAMA 1998; 279(14): 1100–7PubMedCrossRef
4.
Weiss G, Hechtman LT. Hyperactive children grown up. New York: The Guilford Press, 1986
5.
Mannuzza S, Klein RG, Bonagura N, et al. Hyperactive boys almost grown up: V, replication of psychiatric status. Arch Gen Psychiatry 1991; 48(1): 77–83PubMedCrossRef
6.
Fischer M. Persistence of ADHD into adulthood: it depends on whom you ask. ADHD Rep 1997; 5(4): 8–10
7.
Biederman J, Faraone S, Mick E. Age dependent decline of ADHD symptoms revisited: impact of remission definition and symptom subtype. Am J Psychiatry 2000; 157: 816–8PubMedCrossRef
8.
Mannuzza S, Klein RG, Bessler A, et al. Adult outcome of hyperactive boys: educational achievement, occupational rank, and psychiatric status. Arch Gen Psychiatry 1993; 50(7): 565–76PubMedCrossRef
9.
Biederman J, Faraone SV, Spencer T, et al. Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in adults with attention deficit hyperactivity disorder. Am J Psychiatry 1993; 150: 1792–8PubMed
10.
Biederman J, Wilens TE, Mick E, et al. Psychoactive substance use disorders in adults with attention deficit hyperactivity disorder (ADHD): effects of ADHD and psychiatric comorbidity. Am J Psychiatry 1995; 152(11): 1652–8PubMed
11.
Shekim WO, Asarnow RF, Hess E, et al. A clinical and demographic profile of a sample of adults with attention deficit hyperactivity disorder, residual state. Compr Psychiatry 1990; 31: 416–25PubMedCrossRef
12.
Levin FR, Kleber HD. Attention-deficit hyperactivity disorder and substance abuse: relationships and implications for treatment. Harv Rev Psychiatry 1995; 2(5): 246–58PubMedCrossRef
13.
Fones CS, Pollack MH, Susswein L, et al. History of childhood attention deficit hyperactivity disorder (ADHD) features among adults with panic disorder. J Affect Disord 2000; 58(2): 99–106PubMedCrossRef
14.
Alpert J, Maddocks A, Nierenberg A, et al. Attention deficit hyperactivity disorder in childhood among adults with major depression. Psychiatry Res 1996; 62: 213–9PubMedCrossRef
15.
Sachs GS, Baldassano CF, Truman CJ, et al. Comorbidity of attention deficit hyperactivity disorder with early- and late-onset bipolar disorder. Am J Psychiatry 2000; 157(3): 466–8PubMedCrossRef
16.
Shaffer D. Attention deficit hyperactivity disorder in adults. Am J Psychiatry 1994; 151: 633–8PubMed
17.
Hill JC, Schoener EP. Age-dependent decline of attention deficit hyperactivity disorder. Am J Psychiatry 1996; 153: 1143–6PubMed
18.
Spencer T, Biederman J, Wilens T, et al. Adults with attention-deficit/ hyperactivity disorder: a controversial diagnosis. J Clin Psychiatry 1998; 59 Suppl. 7: 59–68PubMed
19.
Achenbach TM, Howell C, McConaughy S, et al. Six-year predictors of problems in a national sample: IV. young adult signs of disturbance. J Am Acad Child Adolesc Psychiatry 1998; 37(7): 718–27CrossRef
20.
Hart EL, Lahey BB, Loeber R, et al. Developmental change in attention-deficit hyperactivity disorder in boys: a four-year longitudinal study. J Abnorm Child Psychol 1995; 23(6): 729–49PubMedCrossRef
21.
Millstein RB, Wilens TE, Biederman J, et al. Presenting ADHD symptoms and subtypes in clincially referred adults with ADHD. J Atten Disord 1997; 2(3): 159–66CrossRef
22.
Sergeant J. A theory of attention: an information processing perspective. In: Lyon G, Krasnegor K, editors. Attention, memory, and executive function. Baltimore (MD): Paul H Brooks, 1996: 57–71
23.
Oosterlaan J, Logan G, Sergeant J. Response inhibition in AD/ HD, CD, comorbid AD/HD + CD, anxious, and control children: a meta-analysis of studies with the stop task. J Child Psychol Psychiatry 1998; 39: 411–25PubMedCrossRef
24.
Barkley RA. ADHD and the nature of self-control. New York: The Guilford Press, 1997
25.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders IV. 4th ed. Washington, DC: American Psychiatric Association Press, 1994
26.
Murphy P, Schachar R. Use of self-ratings in the assessment of symptoms of attention deficit hyperactivity disorder in adults. Am J Psychiatry 2000; 157(7): 1156–9PubMedCrossRef
27.
Ward MF, Wender PH, Reimherr FW. The Wender Utah rating scale: an aid in the retrospective diagnosis of childhood attention deficit hyperactivity disorder. Am J Psychiatry 1993; 150: 885–90PubMed
28.
DuPaul G, Power T, Anastopoulos A, et al. ADHD rating scale IV: checklists, norms, and clinical interpretation. New York: Guilford Press, 1998
29.
Brown T. Brown attention deficit disorder scales. San Antonio (TX): The Psychological Corporation, 1996
30.
Conners C, Jett J. Attention deficit hyperactivity disorder (in adults and children): the latest assessment and treatment strategies. Salt Lake City (UT): Compact Clinicals, 1999
31.
Ratey JJ, Greenberg MS, Bemporad JR, et al. Unrecognized attention-deficit hyperactivity disorder in adults presenting for outpatient psychotherapy. J Child Adolesc Psychopharmacol 1992; 2(4): 267–75PubMedCrossRef
32.
McDermott SP, Wilens TE. Cognitive therapy for adults with ADHD. In: Brown T, editor. Subtypes of attention deficit disorders in children, adolescents, and adults. Washington, DC: American Psychiatric Press Inc, 2000: 569–606
33.
Wilens T, McDermott S, Biederman J, et al. Cognitive therapy in the treatment of adults with ADHD: a systematic chart review of 26 cases. J Cogn Psychother 1999; 13(3): 215–26
34.
Swanson J, McBurnett K, Christian D, et al. Stimulant medications and the treatment of children with ADHD. In: Ollendick T, Prinz R, editors. Advances in clinical child psychology. New York (NY): Plenum Press, 1995: 265–322
35.
Greenhill L, Osman B. Ritalin: theory and practice. New York: Mary Ann Liebert, 1999
36.
Wilens T, Spencer T. The stimulants revisited. In: Stubbe C, editor. Child and Adolescent Psychiatry Clinics of North America. 3rd ed. Philadelphia (PA): Saunders, 2000: 573–603
37.
Wood DR, Reimherr FW, Wender PH, et al. Diagnosis and treatment of minimal brain dysfunction in adults. Arch Gen Psychiatry 1976; 33: 1453–60PubMedCrossRef
38.
Wender PH, Reimherr FW, Wood DR. Attention deficit disorder (‘minimal brain dysfunction’) in adults: a replication study of diagnosis and drug treatment. Arch Gen Psychiatry 1981; 38: 449–56PubMedCrossRef
39.
Wender PH, Reimherr FW, Wood D, et al. A controlled study of methylphenidate in the treatment of attention deficit disorder, residual type, in adults. Am J Psychiatry 1985; 142: 547–52PubMed
40.
Gualtieri CT, Ondrusek MG, Finley C. Attention deficit disorder in adults. Clin Neuropharmacol 1985; 8: 343–56PubMedCrossRef
41.
Mattes JA, Boswell L, Oliver H. Methylphenidate effects on symptoms of attention deficit disorder in adults. Arch Gen Psychiatry 1984; 41: 1059–63PubMedCrossRef
42.
Spencer T, Wilens TE, Biederman J, et al. A double blind, crossover comparison of methylphenidate and placebo in adults with childhood onset attention deficit hyperactivity disorder. Arch Gen Psychiatry 1995; 52: 434–43PubMedCrossRef
43.
Iaboni F, Bouffard R, Minde K, et al. The efficacy of methylphenidate in treating adults with attention-deficit/hyperactivity disorder. Philadelphia (PA): American Academy of Child and Adolescent Psychiatry, 1996
44.
Levin FR, Evans SM, McDowell D, et al. Methylphenidate treatment for cocaine abusers with adult attention-deficit/ hyperactivity disorder: a pilot study. J Clin Psychiatry 1997; 59: 300–5CrossRef
45.
Wilens TE, Biederman J, Spencer TJ, et al. Controlled trial of high doses of pemoline for adults with attention-deficit/ hyperactivity disorder. J Clin Psychopharmacol 1999; 19(3): 257–64PubMedCrossRef
46.
Paterson R, Douglas C, Hallmayer J, et al. A randomised, double-blind, placebo-controlled trial of dexamphetamine in adults with attention deficit hyperactivity disorder. Aust N Z J Psychiatry 1999; 33(4): 494–502PubMedCrossRef
47.
Horrigan J, Barnhill L. Low-dose amphetamine salts and adult attention-deficit/hyperactivity disorder. J Clin Psychiatry 2000; 61: 414–7PubMedCrossRef
48.
Taylor FB. Comparing modafinil to dextroamphetamine in the treatment of adult ADHD. In: 153rd Annual Meeting of the American Psychiatric Association; 2000 May 12–18; Chicago (IL). Chicago (IL): American Psychiatric Association, 2000: NR657
49.
Taylor FB. Comparing guanfacine and dextroamphetamine for adult ADHD: efficacy and implications. In: 153rd Annual Meeting of the American Psychiatric Association; 2000 May 12–18; Chicago (IL). Chicago (IL): American Psychiatric Association, 2000: NR658
50.
Spencer T, Biederman J, Wilens T, et al. Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/ hyperactivity disorder. Arch Gen Psychiatry 2001; 58(8): 775–82PubMedCrossRef
51.
Spencer T. A controlled, long-term trial of methylphenidate in the treatment of adults with ADHD: preliminary data. In: Annual meetings of the American Psychiatric Association; 2002 May 18–23; Philadelphia (PA). Philadelphia (PA): American Psychiatric Association, 2002
52.
Wender PH, Wood DR, Reimherr FW. Pharmacological treatment of attention deficit disorder residual type (ADD,RT, “minimal brain dysfunction”, “hyperactivity”) in adults. Psychopharmacol Bull 1985; 21: 222–30PubMed
53.
Gualtieri CT, Hicks RE. Neuropharmacology of methylphenidate and a neural substrate for childhood hyperactivity. In: Greenhill L, editor. Child and Adolescent Psychiatry Clinics of North America. Philadelphia (PA): WB Saunders Company, 1985: 875–92
54.
Conners C. Rating scales in attention-deficit/hyperactivity disorder: use in assessment and treatment monitoring. In: J Clin Psychiatry 1998; 59 Suppl. 7: 24–30
55.
Faries D, Yalcin I, Harder D, et al. Validation of the ADHD rating scale as a clinican administered and scored instrument. J Atten Disord 2001; 5(2): 107–15CrossRef
56.
NIMH. Clinical Global Impression (CGI). Psychopharmacol Bull 1985; 21: 839–44
57.
Wilens T, Frazier J, Prince J, et al. A double blind comparison of pemoline in adults with ADHD: preliminary results. Scientific proceedings of the American Academy of Child and Adolescent Psychiatry. Philadelphia (PA): American Academy of Child and Adolescent Psychiatry, 1996: 121
58.
Wender P, Reimherr F, Czajkowski L, et al. A longterm trial of methlphenidate in the treatment of adhd adults: a placebo-controlled trial and six-month follow-up. San Juan, Puerto Rico: American College of Neuropharmacology, 1995: 209
59.
Gualtieri CT, Hicks RE, Patrick K, et al. Clinical correlates of methylphenidate blood levels. Ther Drug Monit 1984; 6(4): 379–92PubMedCrossRef
60.
Shevell M, Schreiber R. Pemoline-associated hepatic failure: a critical analysis of the literature. Pediatr Neurol 1996; 16(1): 14–6CrossRef
61.
Langer DH, Sweeney KP, Bartenbach DE, et al. Evidence of lack of abuse or dependence following pemoline treatment: results of a retrospective survey. Drug Alcohol Depend 1986; 17: 213–27PubMedCrossRef
62.
Grabowski J, Roache JD, Schmitz JM, et al. Replacement medication for cocaine dependence: methylphenidate. J Clin Psychopharmacol 1997; 17(6): 485–8PubMedCrossRef
63.
Wilens T, Faraone S, Biederman J, et al. Does the pharmacotherapy of ADHD beget later substance abuse: a metanalytic review of the literature. Pediatrics 2003; 11(1): 179–85CrossRef
64.
Kratochvil CJ, Bohac D, Harrington M, et al. An open-label trial of tomoxetine in pediatric attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 2001; 11(2): 167–70PubMedCrossRef
65.
Spencer T, Biederman J, Heiligenstein J, et al. An open-label, dose-ranging study of tomoxetine in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 2001; 11(5): 251–65PubMedCrossRef
66.
Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/ hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 2001; 108(5): E83PubMedCrossRef
67.
Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with ADHD: a randomized, placebo-controlled study. Am J Psychiatry 2002; 159: 1896–901PubMedCrossRef
68.
Spencer T, Biederman J, Wilens T, et al. Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry 1998; 155(5): 693–5PubMed
69.
Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 2003; 53: 112–20PubMedCrossRef
70.
Wender PH, Reimherr FW. Bupropion treatment of attention deficit hyperactivity disorder in adults. Am J Psychiatry 1990; 147: 1018–20PubMed
71.
Wilens TE, Spencer TJ, Biederman J, et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am J Psychiatry 2001; 158(2): 282–8PubMedCrossRef
72.
Wilens T, Prince J, Biederman J, et al. An open study of sustained-release bupropion in adults with ADHD and substance use disorders. Honolulu (HI): American Academy of Child and Adolescent Psychiatry, 2001
73.
Levin FR, Evans SM, McDowell DM, et al. Bupropion treatment for cocaine abuse and adult attention-deficit/hyperactivity disorder. J Addict Dis 2002; 21(2): 1–16PubMedCrossRef
74.
Wilens T, Prince J, Spencer T, et al. An open trial of bupropion for the treatment of adults with attention deficit hyperactivity disorder and bipolar disorder. Biol Psychiatry 2003; 54: 9–16PubMedCrossRef
75.
Spencer T, Biederman J, Wilens T, et al. Pharmacotherapy of attention deficit disorder across the life cycle. J Am Acad Child Adolesc Psychiatry 1996; 35(4): 409–32PubMedCrossRef
76.
Wilens T, Biederman J, Spencer T. Adverse effects of smoking marijuana while receiving tricyclic antidepressants. J Am Acad Child Adolesc Psychiatr 1997; 36: 45–8CrossRef
77.
Wilens TE, Biederman J, Mick E. A systematic assessment of tricyclic antidepressants in the treatment of adult attention-deficit hyperactivity disorder. J Nerv Ment Dis 1995; 184: 48–50CrossRef
78.
Wilens T, Biederman J, Prince J, et al. Six-week, double blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder. Am J Psychiatry 1996; 153: 1147–53PubMed
79.
Wender PH, Wood DR, Reimherr FW, et al. An open trial of pargyline in the treatment of attention deficit disorder, residual type. Psychiatry Res 1983; 9: 329–36PubMedCrossRef
80.
Ernst M, Liebenauer L, Jons P, et al. Selegiline in adults with attention deficit hyperactivity disorder: clinical efficacy and safety. Psychopharmacol Bull 1996; 32: 327–34PubMed
81.
Zametkin A, Rapoport JL, Murphy DL, et al. Treatment of hyperactive children with momoamine oxidase inhibitors: clinical efficacy. Arch Gen Psychiatr 1985; 42: 962–6PubMedCrossRef
82.
Shekim WO, Masterson A, Cantwell DP, et al. Nomifensine maleate in adult attention deficit disorder. J Nerv Ment Dis 1989; 177: 296–9PubMedCrossRef
83.
Shekim WO, Antun F, Hanna GL, et al. S-adenosyl-l-methionine (SAM) in adults with ADHD, RS: preliminary results from an open trial. Psychopharmacol Bull 1990; 26: 249–53PubMed
84.
Adler LA, Resnick S, Kunz M, et al. Open label trial of venlafaxine in adults with attention deficit disorder. Psychopharmacol Bull 1995; 31: 785–8PubMed
85.
Reimherr FW, Hedges DW, Strong RE, et al. An open trial of venlafaxine in adult patients with attention deficit hyperactivity disorder [poster no. 81]. 35th Annual Meeting of the New Clinical Drug Evaluation Unit; 1995; Orlando (FL)
86.
Findling RL, Schwartz MA, Flannery DJ, et al. Venlafaxine in adults with attention-deficit /hyperactivity disorder: an open clinical trial. J Clin Psychiatry 1996; 57(5): 184–9PubMed
87.
Kurlan R. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology 2002; 58: 527–36CrossRef
88.
Scahill L. Controlled clinical trial of guanfacine in ADHD youth with tic disorders. 40th Annual Meeting of the New Clinical Drug Evaluation Unit; 2000 May 30–Jun 2; Boca Raton (FL)
89.
Mattes JA. Propanolol for adults with temper outbursts and residual attention deficit disorder. J Clin Psychopharmacol 1986; 6: 299–302PubMedCrossRef
90.
Ratey J, Greenberg M, Lindem K. Combination of treatments for attention deficit disorders in adults. J Nerv Ment Dis 1991; 176: 699–701CrossRef
91.
Reimherr FW, Wender PH, Wood DR, et al. An open trial of L-tyrosine in the treatment of attention deficit hyperactivity disorder, residual type. Am J Psychiatry 1987; 144: 1071–3PubMed
92.
Wood D, Reimherr FW. Effects of levodopa on attention deficit disorder, residual type. Psychiatry Res 1982; 6: 13–20PubMedCrossRef
93.
Wood DR, Reimherr FW, Wnder PH. The treatment of attention deficit disorder with d,l-phenylalanine. Psychiatry Res 1985; 16: 21–6PubMedCrossRef
94.
Hedges D, Reimherr FW, Rogers A, et al. An open trial of venlafaxine in adult patients with attention deficit hyperactivity disorder. Psychopharmacol Bull 1995; 31(4): 779–83PubMed
95.
Conners C, Levin ED, Sparrow E, et al. Nicotine and attention in adult attention deficit hyperactivity disorder. Psychopharmacol Bull 1996; 32: 67–73PubMed
96.
Wilens TE, Biederman J, Spencer TJ, et al. A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder. Am J Psychiatry 1999; 156(12): 1931–7PubMed
97.
Kuperman S, Perry PJ, Gaffney GR, et al. Bupropion SR vs methylphenidate vs placebo for attention deficit hyperactivity disorder in adults. Ann Clin Psychiatry 2001; 13(3): 129–34PubMed
98.
Cephalon Inc. No benefit noted from Provigil (Modafinil) in adult attention deficit hyperactivity disorder [press release]. West Chester (PA): Cephalon Inc., 2000 Jul 31
99.
Pomerleau O, Downey K, Stelson F, et al. Cigarette smoking in adult patients diagnosed with attention deficit hyperactivity disorder. J Subst Abuse 1995; 7: 373–8PubMedCrossRef
100.
101.
Wilens T, Biederman J, Spencer T, et al. A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder. Am J Psychiatry 1999; 156: 1931–7PubMed
102.
Mitler MM, Hajdukovich R, Timms R, et al. Treatment of narcolepsy: objective studies on methylphenidate, pemoline, and protriptyline. Sleep 1986; 9: 260–4PubMed
103.
Rapport MD, Carlson GA, Kelly KL, et al. Methylphenidate and desipramine in hospitalized children: I. Separate and combined effects on cognitive function. J Am Acad Child Adolesc Psychiatry 1993; 32: 333–42
104.
Gammon GD, Brown TE. Fluoxetine and methylphenidate in combination for treatment of attention deficit disorder and comorbid depressive disorder. J Child Adolesc Psychopharmacol 1993; 3(1): 1–10PubMedCrossRef
105.
Rapport MD, Jones JT, DuPaul GJ, et al. Attention deficit disorder and methylphenidate: group and single-subject analyses of dose effects on attention in clinic and classroom settings. J Clin Child Psychol 1987; 16: 329–38CrossRef
106.
Rapport MD, Quinn SO, DuPaul GJ, et al. Attention deficit disorder with hyperactivity and methylphenidate: the effects of dose and mastery level on children's learning performance. J Abnorm Child Psychol 1989; 17(6): 669–89PubMedCrossRef
107.
Zametkin A, Liotta W. The neurobiology of attention-deficit/ hyperactivity disorder. J Clin Psychiatry 1998; 59(7): 17–23PubMed
108.
Dougherty D, Bonab A, Spencer T, et al. Dopamine transporter density in patients with attention deficit hyperactivity disorder. Lancet 1999; 354: 2132–3PubMedCrossRef
109.
Krause K, Dresel SH, Krause J, et al. Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: effects of methylphenidate as measured by single photon emission computed tomography. Neurosci Lett 2000; 285(2): 107–10PubMedCrossRef
110.
Faraone SV, Biederman J, Weiffenbach B, et al. Dopamine D4 gene 7-repeat allele and attention deficit hyperactivity disorder. Am J Psychiatry 1999; 156(5): 768–70PubMed
111.
Kuczenski R. Biochemical actions of amphetamine and other stimulants. In: Creese I, editor. Stimulants: neurochemical, behavioral, and clinical perspectives. New York: Raven Press, 1983: 31–61
112.
Elia J, Borcherding BG, Potter WZ, et al. Stimulant drug treatment of hyperactivity: biochemical correlates. Clin Pharmacol Ther 1990; 48: 57–66PubMedCrossRef
113.
Volkow N, Wang G, Fowler J, et al. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry 1998; 155(10): 1325–31PubMed
114.
Volkow ND, Wang GJ, Fowler JS, et al. Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: therapeutic implications. Synapse 2002; 43(3): 181–7PubMedCrossRef
115.
Seiden LS, Sabol KE, Ricaurte GA. Amphetamine: effects on catecholamine systems and behavior. Annu Rev Pharmacol Toxicol 1993; 32: 639–77CrossRef
116.
Wilens T, Spencer T. Pharmacology of amphetamines. In: Tarter R, Ammerman R, Ott P, editors. Handbook of substance abuse: neurobehavioral pharmacology. New York: Plenum Press, 1998: 501–13
117.
Borcherding BG, Keysor CS, Cooper TB, et al. Differential effects of methylphenidate and dextroamphetamine on the motor activity level of hyperactive children. Neuropsychopharmacology 1989; 2: 255–63PubMedCrossRef
118.
Levin E. Nicotinic systems and cognitive function. Psychopharmaology 1992; 108: 417–31CrossRef
119.
Parrott AC, Winder G. Nicotine chewing gum (2mg, 4mg) and cigarette smoking: comparative effects upon vigilance and heart rate. Psychopharmacology (Berl) 1989; 97: 257–61CrossRef
120.
Wesnes K, Warburton D. The effects of cigarettes of varying yield on rapid information processing performance. Psychopharmacology (Berl) 1984; 82: 338–42CrossRef
121.
Jones G, Sahakian B, Levy R, et al. Effects of acute subcutaneous nicotine on attention, information and short-term memory in Alzheimer's disease. Psychopharmacology (Berl) 1992; 108: 485–94CrossRef
122.
Wesnes K, Warburton DM. Smoking, nicotine, and human performance. Pharmacol Ther 1983; 21: 189–208PubMedCrossRef
123.
Pennington BF, Ozonoff S. Executive functions and developmental psychopathology. J Child Psychol Psychiatry 1996; 37(1): 51–87PubMedCrossRef
124.
Brown TE, Quinlan DM. Executive function impairments in high IQ adults with ADHD. New Haven (CT): Yale University School of Medicine, 1999
125.
Seidman LJ, Biederman J, Faraone SV, et al. Toward defining a neuropsychology of ADHD: performance of children and adolescents from a large clinically referred sample. J Consult Clin Psychol 1997; 65(1): 150–60PubMedCrossRef
126.
Levin E, Conners C, Sparrow E, et al. Nicotine effects on adults with attention-deficit/hyperactivity disorder. Psychopharmacology (Berl) 1996; 123: 55–63CrossRef
127.
Hallowell E, Ratey J. Driven to distraction. New York: Pantheon Books, 1994
128.
Spencer T, Biederman J, Wilens T. Pharmacotherapy of attention-deficit/hyperactivity disorder: a life span perspective. In: Dickstein L, Riba M, Oldham J, editors. Review of psychiatry. Washington, DC: American Psychiatric Press, 1998: IV87–IV127
Metadata
Title
Drug Therapy for Adults with Attention-Deficit Hyperactivity Disorder
Author
Dr Timothy E. Wilens
Publication date
01-11-2003
Publisher
Springer International Publishing
Published in
Drugs / Issue 22/2003
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.2165/00003495-200363220-00002

Other articles of this Issue 22/2003

Drugs 22/2003 Go to the issue

Leading Article

Advances in the Understanding and Treatment of Nonalcoholic Fatty Liver Disease

Adis Drug Profile

Emtricitabine

Adis Drug Profile

Emtricitabine

Adis Drug Profile

Novolizer®

Adis Drug Profile

Miglustat

Adis Drug Profile

Emtricitabine